WALTHAM, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at Chardan’s 8th Annual Genetic Medicines Conference being held in New York on Monday, September 30, 2024 at 2:00 p.m. ET. A live webcast will be available in the Investors & Media section ...

MELBOURNE, Australia, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to invite investors to a webinar on October 2, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Genetic Technologies’ senior leadership who will share insight into the Company’s portfolio of genomics-based test ...

EMERYVILLE, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that company management will participate in the following events at Chardan's 8th Annual Genetic Medicines Conference: Fireside chat on Monday, September 30, 2024, 2:30 PM - 3:00 PM ET with Brian Thomas, CEO and Founder, Dr. Sarah Noonberg, CMO, and Alan Brooks, SVP P ...

MELBOURNE, Australia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company has negotiated a partnership agreement with Chicago-based CancerIQ. CancerIQ enables Healthcare Institutions and Clinics to support cancer prevention programs by supporting and simplifying the identification of high-risk patients. Over the past few years, CancerIQ ...

BofA Securities has upgraded Fulcrum Therapeutics FULC ahead of the company’s phase 3 losmapimod readout, expected by the end of October for Facioscapulohumeral muscular dystrophy (FSHD).FSHD is a rare genetic muscle disease affecting a child’s facial muscles, shoulders, upper arms, and lower legs. These muscles weaken and shrink (atrophy).The analyst notes that although a previous pivotal study failed using the DUX4 expression endpoint, the company conducted a post-hoc analysis and designed a new study wit ...

Initial data from largest international Parkinson’s disease patient cohort shows approximately 90% of these genetically confirmed patients had variants in the LRRK2 or GBA1 genes, making these individuals potential candidates to be included in gene-targeted trialsThe Rostock International Parkinson's Disease (ROPAD) Study aims to characterize the genetics of Parkinson’s disease (PD) to establish a better understanding of disease progression, diagnosis, and treatment for patients CAMBRIDGE, Mass. and ROSTOCK ...

CHARLOTTE, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GENE")), a global leader in genomics-based tests in health, wellness and serious disease and the parent company of geneType™, has conducted an operations review and announces that it intends to transition to a capital light operations model – which is anticipated to result in an immediate material reduction in operating costs. This capital light operations model is intended to focus on sales ...

CHARLOTTE, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease and the parent company of geneType™, has conducted an operations review and announces that it intends to transition to a capital light operations model – which is anticipated to result in an immediate material reduction in operating costs. This capital light operations model is intended to focus on sales g ...

MELBOURNE, Australia, July 16, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in genomics-based tests in health, wellness, and serious disease, is pleased to announce the appointment of Mark Ziirsen as Chief Financial Officer (CFO) and Company Secretary. Mark is a globally experienced ASX and Nasdaq listed CFO and company secretary with more than 25 years' experience operating across life sciences, technology and consumer segments that incl ...

MELBOURNE, Australia, July 16, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness, and serious disease, is pleased to announce the appointment of Mark Ziirsen as Chief Financial Officer (CFO) and Company Secretary. Mark is a globally experienced ASX and Nasdaq listed CFO and company secretary with more than 25 years’ experience operating across life sciences, technology and consumer segments that inclu ...